

Feasibility study of bacterial endotoxin testing in hospital preparations of 10% glycerol / 5% fructose

Capucine GRAS GIRARD - Pierre CHAPRON - Annabel GOUBIL - Laura GUIHENEUC - Emmanuelle OLIVIER - Nicolas CORMIER Nantes Université, CHU Nantes, Pharmacie, F-44000, France

COM24-86669



Introduction

In 2023, we initiated the production of injectable glycerol 10% /fructose 5% (GF)

solutions upon the request of gastroenterologists for the excision of intestinal polyps

through interventional endoscopy

The current quality controls include:

- ✓ Sodium determination by ICP-OES*
- √ Osmolarity measurement
- √ pH measurement
- ✓ Sterility test by membrane filtration (Steritest)

*ICP-AES: Induyctively coupled plasma - optic emission spectroscopy

Objective: Study the feasibility of integrating bacterial endotoxin (EB)


testing during routine production to complement quality control of hospital preparation of glycerol/fructose.

Material & Methods

Method D: kinetic colorimetry of the European pharmacopoeia (PE)

(monograph 2.6.14)

- Determination of the maximale significative dilution (MSD)
- Determination of the endotoxin limit concentration (LE)



Selection of samples explore repeatability

- 3 samples tested 7 days after production
- 1 sample tested 50 days after production



Solution Glycérol/Fructose 10%/59

spectrophotometre Endosafe & dedicated cartridge

*WFI: Water for Injection

Results



LE determination

Administrated submucosally > parenteral route

LE = K/M (thanks to PE)

K: threshold dose of endotoxin per Kg (K= 100 IU/m²) M: Maximum recommended dose for product per Kg

Standard patient: 70 Kg, body surface 1.8m², 100ml of GF solution injected $K = (100 \times 1.8) / 70 = 2.5 UI/ kg$ M = 100/70 = 1.42 ml/kg

 $LE = 1.76 \, IU/ml$

MSD determination

Detection limit of the cartridge is 0.05 - 5 IU/ mL relative to the MSD, corresponding to an actual detection range of $0.05 \times MSD$ and $5 \times MSD$

Tests performed: MSD 50 and MSD 25

Range obtained must include the LE chosen

> MSD = 25Final detection range used: 1.25 - 125 IU/ml

Endosafe nexgen-PTS rapport de test*

Manipulation

- 5 minutes handling
- 15 minutes acquisition

Conformity Tests

- Recovery rate 50-200%
- Sample reaction time CV* < 25%
- Spike reaction time CV < 25%
- Positive control included in the cartridge

*CV: Variation coefficient

Endosare nexgen-ris rappore de cese
Version: PTS150 V11.0.0
Date / Heure: 17/02/24 00:09
N° série Lecteur: 20331116
Analyste: CGG
Cartouche: Endotoxin
Température: Début: 37.0C Fin: 37.0C
Méthode: KX-122
Cartouche Lot #: 3913159
Cartouche code Cal: 513936975493
Gamme: 5-0.05
Temps de Réact. gamme: Sec: 139-769
Temps de réact. Puits: >769 226 >769 214
Pente:0.371 Interception: +2.403
Dilution: 1:25
Lot échantillon:
Nom de l'échantillon:4
CV temps Echantillon: 0.0% Réussir
Valeur Surcharge: 1.40 EU/mL
CV temps Surcharge: 3.9% Réussir
% de Recouvrement: 190% Réussir
Test de conformité: Réussir
Conc. Endotoxine: <1.25 EU/mL \$271a67997e8af3f118b402e3fa6ec653c384a390
\$2/1d0/99/eod1311100402e31d0eC033C304d390

Conclusion



Sample form our tested productions are free from detectable endotoxins at the threshold of 1.25 IU/ml



Feasibility study concluded, encouraging the integration of EB measurement into routine practice:

- short acquisition time
- easy to use device (*Purchase of the* device under study)
- no additional skills required
- cost of a control: 50€/ cartridge, or 150€ per production batch

For the future?

Adjustment of production: Volume of GF solution bags increased to 250 mL to meet the clinicians' requirements.



Adjust LE and MSD values to be applied for routine measurement of this new solution volume.

